Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q1 FY25 results · Apr–Jun 2024
Dr. Lal Path Labs reported revenue from operations of ₹601.90 crore (up 11.3% from Q1 FY24) and net profit of ₹107.80 crore (up 28.9% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 601.90 | 541.00 | +11.3% | 545.40 | +10.4% |
| Other income | 20.60 | 14.40 | +43.1% | 18.40 | +12.0% |
| Total income | 622.50 | 555.40 | +12.1% | 563.80 | +10.4% |
| Profit before tax | 149.90 | 117.50 | +27.6% | 119.90 | +25.0% |
| Net profit for the period | 107.80 | 83.60 | +28.9% | 85.80 | +25.6% |
| Attributable to shareholders of the company | 106.40 | 82.60 | +28.8% | 84.50 | +25.9% |
| EPS, basic (₹) | 12.79 | 9.95 | +28.5% | 10.13 | +26.3% |
| Net margin (%) | 17.9 | 15.5 | 15.7 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 534.50 | 480.10 | +11.3% | 479.00 | +11.6% |
| Other income | 28.80 | 15.00 | +92.0% | 15.90 | +81.1% |
| Total income | 563.30 | 495.10 | +13.8% | 494.90 | +13.8% |
| Profit before tax | 161.00 | 125.10 | +28.7% | 120.50 | +33.6% |
| Net profit for the period | 122.90 | 93.60 | +31.3% | 89.50 | +37.3% |
| EPS, basic (₹) | 14.76 | 11.28 | +30.9% | 10.73 | +37.6% |
| Net margin (%) | 23.0 | 19.5 | 18.7 |
Consolidated
- Filed with BSE
- 08 Aug 2024, 11:36 IST
- Board meeting
- 07 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2024, 11:36 IST
- Board meeting
- 07 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE